Menu Search
Equities

Denali Therapeutics Inc

DNLI:NSQ

Denali Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)31.05
  • Today's Change0.29 / 0.94%
  • Shares traded943.47k
  • 1 Year change+40.56%
  • Beta1.3422
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy6
Outperform9
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Denali Therapeutics Inc have a median target of 35.00, with a high estimate of 90.00 and a low estimate of 22.00. The median estimate represents a 12.72% increase from the last price of 31.05.
High189.9%90.00
Med12.7%35.00
Low-29.1%22.00

Earnings history & estimates in USD

On Aug 01, 2024, Denali Therapeutics Inc reported 2nd quarter 2024 losses of -0.590 per share. This result exceeded the -0.69 consensus loss of the 16 analysts covering the company and under-performed last year's 2nd quarter results by -1.89.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate+4.91%
Denali Therapeutics Inc reported annual 2023 losses of -1.06 per share on Feb 27, 2024.
Average growth rate+25.22%
More ▼

Revenue history & estimates in USD

Denali Therapeutics Inc. did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 35.14m.
Average growth rate-49.89%
Denali Therapeutics Inc. had revenues for the full year 2023 of 330.53m. This was 204.74% above the prior year's results.
Average growth rate+350.06%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.